Outlook Therapeutics, Inc.
5 clinical trials · Sponsor
◉ Watch Outlook Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) (NCT06190093) | Outlook Therapeutics, Inc. | 2024-01-24 |
| A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders (NCT05112861) | Outlook Therapeutics, Inc. | 2021-11-15 |
| A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders (NCT04516278) | Outlook Therapeutics, Inc. | 2020-10-01 |
| A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) (NCT03834753) | Outlook Therapeutics, Inc. | 2019-06-25 |
| A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) (NCT03844074) | Outlook Therapeutics, Inc. | 2018-10-01 |
Track Outlook Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.